发明名称 |
New hirudin-poly:alkylene glycol conjugate(s) - used as anticoagulants for treatment and prophylaxis of myocardial infarct, arterial occlusion, venous thrombosis and pulmonary embolism |
摘要 |
Hirudin-polyalkylene glycol conjugates (I) (A-(CH2)n-(O-(CH2)n)m-B-)pHir are new. In (I): A=OH, NH2, CH3CONH, COOH, COOR or OR; R = 1-4C alkyl; B = direct bond or a linker; Hir = hirudin, desulphatohirudin or hirudin mutein gp. linked via serine, threonine or lysine chain(s); m = 100-1000; n = 2-5; p = 1-4. Pref. the linker is (a) -O-(CH2)n-1-CH= or -O-(CH2)n-1-CO-; or (b) -X-CO-, -X-CO-NH-Z-NH-CO-, -X-CH2-p-Ph-N2-, -X-CH2-CH(OH)-CH2-p-Ph-N2-, -X-CO-CH2-CH2-CO-, -X-CH2-CO- or gp. of formula (i); R1 = H, Cl or OH; X = -S-, -O-, -N(H, CH3 or C2H5)-; and Z = 2-6C alkylene or p-phenylene. USE/ADVANTAGE - (I) are anticoagulants in human and veterinary medicine to treat and prevent e.g. myocardial infarct, peripheral arterial occlusions, deep vein thrombosis and pulmonary embolism. They are administered i.v. or i.m. (I) have a half-life of 1-100 hours, compared with 50 mins. for hirudin itself and 7 hours for hirudin-dextran. Further, (I) have high activity with only very slight antigenicity.
|
申请公布号 |
DE4014260(A1) |
申请公布日期 |
1991.06.06 |
申请号 |
DE19904014260 |
申请日期 |
1990.05.04 |
申请人 |
BASF AG, 6700 LUDWIGSHAFEN, DE |
发明人 |
KURFUERST, MANFRED, DR., 6733 HASSLOCH, DE;RUEBSAMEN, KLAUS, DR., 6730 NEUSTADT, DE;SCHMIED, BERNHARD, DR., 6710 FRANKENTHAL, DE |
分类号 |
A61K38/00;A61K47/48;C07K14/815 |
主分类号 |
A61K38/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|